AB1226 The diagnostic value of serum kl-6 in connective tissue disease associated interstitial lung disease

Background The connective tissue diseases is a group of inflammatory, immune-mediated diseases.CTD often leads to autoimmunity and subsequent tissue injury. It is an important contribute to thoracic changes, particularly interstitial lung disease, is are the main causes of mortality and morbidity among patients with connective tissue diseases. Prognosis and response to therapy are the most pressing challenges for connective tissue disease-associated ILD (CTD-ILD). At present, the basic methods for the diagnosis of various types of ILD includes high-resolution computed tomography, bronchoscopy, and surgical lung biopsy. In addition, continuous lung function tests are commonly used to monitor disease activity and predict the outcome of patients with ILDs, But these tests require specific inspection machines and Repeatability is not good. At present, many biomarkers have been developed to detect ILDs, and the most important biomarkers is KL-6 and lung surface active protein A (SP- A) and surfactant protein D (SP – D) witch secreted by alveolar epithelial type II cells. But Relevant studies have shown that the sensitivity, specificity and accuracy of KL-6 are higher than SP-A and SP-D. Objectives To evaluate the diagnosis of the serum Krebs von den Lungen-6 (KL-6) for the interstitial lung disease(ILD) associated with connective tissue diseases(CTD). Methods We retrospectively analysed the medical records of 50 patients with CTD associated ILD,46 CTD patients without ILD. Measurement of serum KL-6 levels and pulmonary function tests performed in parallel were reviewed.T test, X2 test, non-parametric test, SPSS and correlation analysis were used for data analysis. Results The significantly higher levels of KL-6 were determined in the CTD-ILD group than in either the CTD without pulmonary involvement group(P Conclusions The serum KL-6 is a valuable biomarker for CTD-ILD diagnosis and even as a predictive factor could be used to identify the clinical development of ILD. Disclosure of Interest None declared